American Heart Association
American Heart Association Late-breaking Clinical Trial Report: Risks of Anemia Drug Outweigh Benefits in Cardiovascular Disease Patients With Diabetes and Kidney Disease
Published in Medical Patent Week, December 6th, 2009
Earlier results of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT), reported at a recent meeting of the American Society of Nephrology, showed that use of darbepoetin alfa to raise hemoglobin levels in patients with type 2 diabetes, chronic kidney disease (without dialysis) and moderate anemia (low red cell blood count) lessened the need for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Week
Source: Medical Patent Week (2009-12-06)
More Articles from Medical Patent Week
- American Biotech Labs, Llc
American Biotech Labs Receives FDA Clearance for New Prescription Wound Dressing Gel - Apieron, Inc.
Apieron Alleges Evidence Shows Aerocrine Inventors Withheld Prior Art Information from Patent Office - Article One Partners
Article One Partners Becomes World's Largest Patent Validation Firm - Bioscience
Hungarian Cancer Formula Producer Questions U.S. Introduction of AveUltra - Diabetic Retinopathy
Sales of Therapies to Treat Diabetic Retinopathy, Diabetic Neuropathy and Diabetic Nephropathy Will Increase by More Than 70 Percent Through 2018 - Entest BioMedical Inc.
Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment - More from this issue of Medical Patent Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
